{"pmid":32332922,"title":"SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2.","text":["SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2.","Nat Rev Nephrol","Allison, Susan J","32332922"],"journal":"Nat Rev Nephrol","authors":["Allison, Susan J"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32332922","week":"202017|Apr 20 - Apr 26","doi":"10.1038/s41581-020-0291-8","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1665071049747726336,"score":8.518259,"similar":[{"pmid":32333836,"title":"Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.","text":["Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.","We have previously provided the first genetic evidence that angiotensin converting enzyme 2 (ACE2) is the critical receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), and ACE2 protects the lung from injury, providing a molecular explanation for the severe lung failure and death due to SARS-CoV infections. ACE2 has now also been identified as a key receptor for SARS-CoV-2 infections, and it has been proposed that inhibiting this interaction might be used in treating patients with COVID-19. However, it is not known whether human recombinant soluble ACE2 (hrsACE2) blocks growth of SARS-CoV-2. Here, we show that clinical grade hrsACE2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1,000-5,000. An equivalent mouse rsACE2 had no effect. We also show that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids, which can be inhibited by hrsACE2. These data demonstrate that hrsACE2 can significantly block early stages of SARS-CoV-2 infections.","Cell","Monteil, Vanessa","Kwon, Hyesoo","Prado, Patricia","Hagelkruys, Astrid","Wimmer, Reiner A","Stahl, Martin","Leopoldi, Alexandra","Garreta, Elena","Hurtado Del Pozo, Carmen","Prosper, Felipe","Romero, Juan Pablo","Wirnsberger, Gerald","Zhang, Haibo","Slutsky, Arthur S","Conder, Ryan","Montserrat, Nuria","Mirazimi, Ali","Penninger, Josef M","32333836"],"abstract":["We have previously provided the first genetic evidence that angiotensin converting enzyme 2 (ACE2) is the critical receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), and ACE2 protects the lung from injury, providing a molecular explanation for the severe lung failure and death due to SARS-CoV infections. ACE2 has now also been identified as a key receptor for SARS-CoV-2 infections, and it has been proposed that inhibiting this interaction might be used in treating patients with COVID-19. However, it is not known whether human recombinant soluble ACE2 (hrsACE2) blocks growth of SARS-CoV-2. Here, we show that clinical grade hrsACE2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1,000-5,000. An equivalent mouse rsACE2 had no effect. We also show that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids, which can be inhibited by hrsACE2. These data demonstrate that hrsACE2 can significantly block early stages of SARS-CoV-2 infections."],"journal":"Cell","authors":["Monteil, Vanessa","Kwon, Hyesoo","Prado, Patricia","Hagelkruys, Astrid","Wimmer, Reiner A","Stahl, Martin","Leopoldi, Alexandra","Garreta, Elena","Hurtado Del Pozo, Carmen","Prosper, Felipe","Romero, Juan Pablo","Wirnsberger, Gerald","Zhang, Haibo","Slutsky, Arthur S","Conder, Ryan","Montserrat, Nuria","Mirazimi, Ali","Penninger, Josef M"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333836","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.cell.2020.04.004","keywords":["covid-19","angiotensin converting enzyme 2","blood vessels","human organoids","kidney","severe acute respiratory syndrome coronavirus","spike glycoproteins","treatment"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1665071049647063042,"score":64.33626},{"pmid":32303993,"title":"Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids.","text":["Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids.","Protein Cell","Zhao, Bing","Ni, Chao","Gao, Ran","Wang, Yuyan","Yang, Li","Wei, Jinsong","Lv, Ting","Liang, Jianqing","Zhang, Qisheng","Xu, Wei","Xie, Youhua","Wang, Xiaoyue","Yuan, Zhenghong","Liang, Junbo","Zhang, Rong","Lin, Xinhua","32303993"],"journal":"Protein Cell","authors":["Zhao, Bing","Ni, Chao","Gao, Ran","Wang, Yuyan","Yang, Li","Wei, Jinsong","Lv, Ting","Liang, Jianqing","Zhang, Qisheng","Xu, Wei","Xie, Youhua","Wang, Xiaoyue","Yuan, Zhenghong","Liang, Junbo","Zhang, Rong","Lin, Xinhua"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303993","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s13238-020-00718-6","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1664632934583238656,"score":50.76276},{"pmid":32275855,"pmcid":"PMC7144619","title":"Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","text":["Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.","The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus.","Cell","Wang, Qihui","Zhang, Yanfang","Wu, Lili","Niu, Sheng","Song, Chunli","Zhang, Zengyuan","Lu, Guangwen","Qiao, Chengpeng","Hu, Yu","Yuen, Kwok-Yung","Wang, Qisheng","Zhou, Huan","Yan, Jinghua","Qi, Jianxun","32275855"],"abstract":["The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus."],"journal":"Cell","authors":["Wang, Qihui","Zhang, Yanfang","Wu, Lili","Niu, Sheng","Song, Chunli","Zhang, Zengyuan","Lu, Guangwen","Qiao, Chengpeng","Hu, Yu","Yuen, Kwok-Yung","Wang, Qisheng","Zhou, Huan","Yan, Jinghua","Qi, Jianxun"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275855","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.cell.2020.03.045","keywords":["ace2","ctd","sars-cov-2","crystal structure","immunogenicity","receptor","receptor binding domain"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637190193283072,"score":41.052727}]}